• Something wrong with this record ?

Nano-formulated curcumin (LipodisqTM) modulates the local inflammatory response, reduces glial scar and preserves the white matter after spinal cord injury in rats

P. Krupa, B. Svobodova, J. Dubisova, S. Kubinova, P. Jendelova, L. Machova Urdzikova,

. 2019 ; 155 (-) : 54-64. [pub] 20190517

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc20006350

A highly water soluble, nano-formulated curcumin was used for the treatment of the experimental model of spinal cord injury (SCI) in rats. Nanocurcumin and a vehicle nanocarrier as a control, were delivered both locally, immediately after the spinal cord injury, and intraperitoneally during the 4 consecutive weeks after SCI. The efficacy of the treatment was assessed using behavioral tests, which were performed during the experiment, weekly for 9 weeks. The behavioral tests (BBB, flat beam test, rotarod, motoRater) revealed a significant improvement in the nanocurcumin treated group, compared to the nanocarrier control. An immunohistochemical analysis of the spinal cord tissue was performed at the end of the experiment and this proved a significant preservation of the white matter tissue, a reduced area of glial scaring and a higher amount of newly sprouted axons in the nanocurcumin treated group. The expression of endogenous genes (Sort1, Fgf2, Irf5, Mrc1, Olig2, Casp3, Gap43, Gfap, Vegf, Nfkβ) and interleukins (IL-1β, TNF-α, IL-6, IL-12, CCL-5, IL-11, IL-10, IL-13) was evaluated by qPCR and showed changes in the expression of the inflammatory cytokines in the first two weeks after SCI.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006350
003      
CZ-PrNML
005      
20240703135140.0
007      
ta
008      
200511e20190517xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.neuropharm.2019.05.018 $2 doi
035    __
$a (PubMed)31108112
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Krupa, Petr $u Institute of Experimental Medicine, Czech Academy of Sciences, Vídeňská 1083, Prague, Czech Republic; Department of Neurosurgery, Charles University, Medical Faculty and University Hospital Hradec Králové, Sokolska 581, Hradec Kralove, Czech Republic. Electronic address: petr.krupa@iem.cas.cz.
245    10
$a Nano-formulated curcumin (LipodisqTM) modulates the local inflammatory response, reduces glial scar and preserves the white matter after spinal cord injury in rats / $c P. Krupa, B. Svobodova, J. Dubisova, S. Kubinova, P. Jendelova, L. Machova Urdzikova,
520    9_
$a A highly water soluble, nano-formulated curcumin was used for the treatment of the experimental model of spinal cord injury (SCI) in rats. Nanocurcumin and a vehicle nanocarrier as a control, were delivered both locally, immediately after the spinal cord injury, and intraperitoneally during the 4 consecutive weeks after SCI. The efficacy of the treatment was assessed using behavioral tests, which were performed during the experiment, weekly for 9 weeks. The behavioral tests (BBB, flat beam test, rotarod, motoRater) revealed a significant improvement in the nanocurcumin treated group, compared to the nanocarrier control. An immunohistochemical analysis of the spinal cord tissue was performed at the end of the experiment and this proved a significant preservation of the white matter tissue, a reduced area of glial scaring and a higher amount of newly sprouted axons in the nanocurcumin treated group. The expression of endogenous genes (Sort1, Fgf2, Irf5, Mrc1, Olig2, Casp3, Gap43, Gfap, Vegf, Nfkβ) and interleukins (IL-1β, TNF-α, IL-6, IL-12, CCL-5, IL-11, IL-10, IL-13) was evaluated by qPCR and showed changes in the expression of the inflammatory cytokines in the first two weeks after SCI.
650    _2
$a zvířata $7 D000818
650    _2
$a jizva $x farmakoterapie $x metabolismus $x patologie $7 D002921
650    _2
$a kurkumin $x aplikace a dávkování $7 D003474
650    _2
$a příprava léků $7 D004339
650    _2
$a mediátory zánětu $x antagonisté a inhibitory $x metabolismus $7 D018836
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a nanočástice $x aplikace a dávkování $7 D053758
650    _2
$a neuroglie $x účinky léků $x metabolismus $x patologie $7 D009457
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
650    _2
$a poranění míchy $x farmakoterapie $x metabolismus $x patologie $7 D013119
650    _2
$a bílá hmota $x účinky léků $x metabolismus $x patologie $7 D066127
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Svobodova, Barbora $u Institute of Experimental Medicine, Czech Academy of Sciences, Vídeňská 1083, Prague, Czech Republic; Department of Neuroscience, Charles University, Second Faculty of Medicine, Prague, Czech Republic. Electronic address: barbora.svobodova@iem.cas.cz.
700    1_
$a Dubisova, Jana $u Institute of Experimental Medicine, Czech Academy of Sciences, Vídeňská 1083, Prague, Czech Republic; Department of Neuroscience, Charles University, Second Faculty of Medicine, Prague, Czech Republic. Electronic address: jana.dubisova@biomed.cas.cz.
700    1_
$a Kubinova, Sarka $u Institute of Experimental Medicine, Czech Academy of Sciences, Vídeňská 1083, Prague, Czech Republic. Electronic address: sarka.kubinova@iem.cas.cz.
700    1_
$a Jendelova, Pavla $u Institute of Experimental Medicine, Czech Academy of Sciences, Vídeňská 1083, Prague, Czech Republic; Department of Neuroscience, Charles University, Second Faculty of Medicine, Prague, Czech Republic. Electronic address: pavla.jendelova@iem.cas.cz.
700    1_
$a Machová Urdzíková, Lucia $u Institute of Experimental Medicine, Czech Academy of Sciences, Vídeňská 1083, Prague, Czech Republic; Department of Neuroscience, Charles University, Second Faculty of Medicine, Prague, Czech Republic. Electronic address: lucia.machova@iem.cas.cz. $7 xx0136406
773    0_
$w MED00003497 $t Neuropharmacology $x 1873-7064 $g Roč. 155 (20190517), s. 54-64
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31108112 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20240703135135 $b ABA008
999    __
$a ok $b bmc $g 1525208 $s 1096406
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 155 $c - $d 54-64 $e 20190517 $i 1873-7064 $m Neuropharmacology $n Neuropharmacology $x MED00003497
LZP    __
$a Pubmed-20200511

Find record

Citation metrics

Archiving options